Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

0.2700 +0.0030 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
News headline image
Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) shares are trading lower by 17.13% to $2.95 Tuesday morning after the company announced a $2.1 million registered direct offe 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Via ACCESSWIRE
News headline image
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumb 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar disc disease,... 
Via Benzinga
News headline image
BioResorative CEO is Featured in An Interview With SmallCaps Daily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
News headline image
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
Via ACCESSWIRE
News headline image
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It ↗
Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise. 
Via Benzinga
News headline image
EXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain Trial ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) announced that the final subject in its BRTX-100 Phase 2 trial safety cohort has been dosed. 
Via Benzinga
News headline image
EXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell Processing ↗
BioRestorative Therapies, Inc (NASDAQ: BRTX), bagged a license from the New York State Department of Health to act as a tissue bank for processing  
Via Benzinga
News headline image
A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate ↗
Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc (NASDAQ: BRTX) in... 
Via Benzinga
News headline image
EXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese Patent ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to its metabolic ThermoStem... 
Via Benzinga
News headline image
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
Via ACCESSWIRE
News headline image
EXCLUSIVE: BioRestorative Therapies & Northwell Health Ink Trial Pact For Chronic Lower Back Pain Study ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has signed a clinical trial agreement with Northwell Health and Northwell's Feinstein Institutes for Medical Research to participate in the company's Phase 2... 
Via Benzinga
BioRestorative Therapies, Inc. (NASDAQ: BRTX) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
News headline image
EXCLUSIVE: BioRestorative Concludes Enrollment For Safety Run-In Component Of Cell Therapy Study For Chronic Lower Back Pain ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has completed enrollment for the safety run-in component of its Phase 2 study of BRTX-100 targeting patients suffering from chronic lumbar disc disease... 
Via Benzinga
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion 
Via News Direct
Topics Intellectual Property
News headline image
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome... 
Via Benzinga
News headline image
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? ↗
Successful Autologous Cell-Based Therapies 
Via Benzinga
News headline image
EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for... 
Via Benzinga
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome ↗
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.